SCHEMBL4288247

SCHEMBL4288247

CCOc1ccc(Nc2ncc3ccn(-c4ccc(CN5CCOCC5)c(Cl)c4)c3n2)cc1OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 2/20 0.46
▸ BRD4 O60885 7/20 0.45
▸ JAK2 O60674 6/20 0.45
▸ PTK2 Q05397 5/20 0.44
▸ STAT6 P42226 4/20 0.44
▸ AURKA O14965 2/20 0.44
▸ CDK4 P11802 2/20 0.44
▸ PDGFRB P09619 2/20 0.42
▸ FGFR1 P11362 2/20 0.42
▸ PDGFRA P16234 2/20 0.42
▸ SLC2A1 P11166 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ PKMYT1 Q99640 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ PAK4 O96013 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ CSF1R P07333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1657607 0.89 PTK2 (0.54) RPS6KA3BRD4JAK2PTK2STAT6
SCHEMBL1655251 0.85 STAT6 (0.49) RPS6KA3BRD4JAK2PTK2STAT6
SCHEMBL1654949 0.84 AURKA (0.47) RPS6KA3BRD4JAK2PTK2STAT6
SCHEMBL13745991 0.84 STAT6 (0.51) RPS6KA3BRD4JAK2STAT6AURKA
SCHEMBL1655094 0.81 JAK2 (0.55) RPS6KA3BRD4JAK2PTK2STAT6
SCHEMBL1656024 0.81 RPS6KA3 (0.53) RPS6KA3BRD4JAK2STAT6AURKA
SCHEMBL1654525 0.78 RPS6KA3 (0.53) RPS6KA3BRD4JAK2PTK2STAT6
SCHEMBL1655195 0.77 STAT6 (0.43) BRD4JAK2STAT6AURKACDK4
SCHEMBL4289910 0.77 JAK2 (0.55) RPS6KA3BRD4JAK2STAT6AURKA
SCHEMBL1654970 0.75 RPS6KA3 (0.54) RPS6KA3BRD4JAK2PTK2STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US claimed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US claimed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885BRD4 964/4885JAK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback